Effects of LY117018 and the Estrogen Analogue, 17α-Ethinylestradiol, on Vascular Reactivity, Platelet Aggregation, and Lipid Metabolism in the Insulin-Resistant JCR:LA-cp Male Rat: Role of Nitric Oxide
- 1 January 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 37 (1) , 119-128
Abstract
The JCR:LA-cp rat is obese and insulin resistant and develops a major vasculopathy, with associated ischemic damage to the heart. Male rats were treated with 17α-ethinylestradiol (EE), LY117018, and/or the nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME). LY117018 decreased plasma cholesterol esters, with a 40% reduction in total cholesterol. EE increased triglyceride levels and modestly decreased cholesterol esters. L-NAME increased blood pressure and aortic contractile sensitivity to phenylephrine and inhibited acetylcholine-induced relaxation. LY117018 decreased the force of contraction. The L-NAME-mediated increase in force of contraction and decrease in response to acetylcholine was inhibited by LY117018. L-NAME-induced hypertension was prevented by LY117018. Platelet aggregation was not different between obese and lean rats and was unaffected by L-NAME. LY117018, both in the absence and presence of L-NAME, inhibited platelet aggregation. The effects of LY117018 are apparently mediated through both NO-dependent and -independent mechanisms. The changes induced by EE and LY117018 may reflect the activation of multiple mechanisms, both estrogen receptor-dependent and -independent. The changes induced by LY117018 are significant and may prove to be cardioprotective in the presence of the insulin resistance syndrome.Keywords
This publication has 33 references indexed in Scilit:
- Development of insulin resistance in the JCR:LA-cp rat: role of triacylglycerols and effects of MEDICA 16.Diabetes, 1998
- Vasculopathy and insulin resistance in the JCR:LA-cp ratAtherosclerosis, 1998
- Diabetes Mellitus and Associated Hypertension, Vascular Disease, and NephropathyHypertension, 1995
- Nitric oxide— biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosisAtherosclerosis, 1995
- Inhibition of Atherosclerosis and Myocardial Lesions in the JCR:LA-cp Rat by β,β′-Tetramethylhexadecanedioic Acid (MEDICA 16)Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991
- Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivoBritish Journal of Pharmacology, 1990
- l‐NG‐nitro arginine (l‐NOARG), a novel, l‐arginine‐reversible inhibitor of endothelium‐dependent vasodilatation in vitroBritish Journal of Pharmacology, 1990
- Role of endothelium-derived nitric oxide in the regulation of blood pressure.Proceedings of the National Academy of Sciences, 1989
- Menopause and Risk of Cardiovascular DiseaseAnnals of Internal Medicine, 1976